Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. - Wikidata - wikimedia - TriplyDB

Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

http://www.wikidata.org/entity/Q33840789

about

Recent strategies targeting HIV glycans in vaccine design Designing synthetic vaccines for HIV Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection Glycan microarrays for decoding the glycome.Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates Synthetic carbohydrate antigens for HIV vaccine design.Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections Multivalent glycocluster design through directed evolution.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.High sensitive detection of carbohydrate binding proteins in an ELISA-solid phase assay based on multivalent glyconanoparticles.Directed evolution of multivalent glycopeptides tightly recognized by HIV antibody 2G12.The art of engineering viral nanoparticles.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.Multivalent glycoconjugates as anti-pathogenic agents High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.Development of prophylactic vaccines against HIV-1.Boosting immunity to small tumor-associated carbohydrates with bacteriophage qβ capsids.Glycomaterials for probing host-pathogen interactions and the immune response.Carbohydrate vaccines: developing sweet solutions to sticky situations?Carbohydrate-based vaccines: challenges and opportunities.Carbohydrate chemistry in drug discovery.Toward automated oligosaccharide synthesis.Vaccines based on structure-based design provide protection against infectious diseases.Functionalization of protein-based nanocages for drug delivery applications.Synthetic and bioinspired cage nanoparticles for drug delivery.Synthesis of high-mannose 1-thio glycans and their conjugation to protein.Viral chemistry: the chemical functionalization of viral architectures to create new technology.Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12.Polymer Structure and Conformation Alter the Antigenicity of Virus-like Particle-Polymer Conjugates.Synthetically defined glycoprotein vaccines: current status and future directions.Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.Altering the landscape of viruses and bionanoparticles.

P2860

Q26823603-3B589CA8-CAD0-4C3E-B7F9-4D01273FA544 Q26862617-9D707CBC-9224-466E-9D7F-81E7B3A0AC9A Q27664038-4966EACC-DBBF-4D93-BE2E-D2A87A50CDA6 Q27664589-28F3BEBE-FED8-4305-AEF7-B2E2B391EA0B Q30354064-FB96BE0E-C920-435B-A718-ABEEA21E319B Q30531089-9645CD38-5474-45AE-BCC3-9C6287D288DC Q31004845-62834126-3548-4730-8E0E-1BEC3080E2A3 Q33612459-88065EC4-56B5-4C61-99E3-8081184744BE Q33909079-D8A0DCD0-CAC3-423B-A1E7-AF54037EFEFA Q34042642-E229E234-1B31-4C41-9843-A2D633D0BE86 Q34108462-3157A64D-727D-45A8-80F4-C63638E933F6 Q34551010-0D7E2E1E-60C8-4534-BBF8-3F135F026A62 Q34981074-CBD72E74-32C1-4DA7-9D8A-D4381BB9B98F Q35124652-8021D5B6-2DB2-4470-9DCD-A1C6A95F5963 Q35165714-FCE66A6C-8F20-48E0-8F6F-77387C54ED79 Q35174495-9B991CE1-EDD4-4A68-A1D7-A17BD61749AA Q35444698-7991F514-5A77-47A5-9386-1AA938F0A1E3 Q35826509-152BC8AF-5BE6-48EF-A7A8-F1322D3349A2 Q36079874-3CE960C0-281C-432F-B49C-806F66A7A21E Q36497647-B4583B69-6D6D-4FE0-A88A-E096C11421CE Q36501284-CD954F45-44D2-480B-A8D4-B69A10333420 Q36607316-9E6B9923-AACA-44E5-B055-3208C6AEECD1 Q37042563-582E95F3-FB41-4ECC-8CCE-D6F9CC700F53 Q37076109-6C7ED1AF-B270-4B04-93E0-D7729956BE46 Q37107154-A0914064-27AA-4284-841D-F911134D7F1A Q37426039-DEF868BE-706D-461D-8CDD-1DE0E68911C1 Q37810597-C4FE3C3B-08E1-4712-ABDC-2756215E621A Q37853437-27E5A308-B0DF-44E7-8CE0-572FFEB83A86 Q37962848-2E029A7F-CC1B-456E-81CC-10F8A5582692 Q38148782-97615E83-1354-4ADC-B5B2-16EEA3900E8E Q38214775-C61238BB-B749-4935-BF6E-948DE27BB755 Q38254088-2A9A61B6-5842-4B1F-AB3E-E2829BC3B4DD Q38308862-26D1C770-0830-46CB-98B3-86E3FC46C4BB Q38668484-FEE10F5A-34FA-4528-9ACC-E05E4449E95E Q38695294-DFAA051A-CFE8-41B9-AB0D-782BA5F55F18 Q38732360-4E87AC43-BF36-4758-A6E4-0F37F0253D15 Q39000229-1A2D922B-9489-49F2-B810-BD96DE894419 Q39375701-6AD33F63-6E60-4127-96F6-A10ACF767BD0 Q39430508-00302D3F-22AE-4F02-A80E-A355219D140D Q39729448-C50E4DEE-AC8C-4652-BA33-04937BEE2B79

P2860

Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

http://www.wikidata.org/entity/Q33840789

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@ast

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@en

type

label

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@ast

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@en

prefLabel

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@ast

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@en

P1433

Q33840789-FB2E22E6-66B3-4D6C-B6AA-0BA220AE2293

P1476

Q33840789-8D833976-26ED-43D9-994C-F47294F21CA5

P2093

Q33840789-1D5ED459-1AD7-41E7-9B8E-9B1D95C9EA87

Q33840789-33C4D57B-7DCF-49CA-B2B5-93F83D562DB7

Q33840789-33F405B7-240D-4F82-9F05-BEB9A4F5F348

Q33840789-3D0C0F60-1F74-4D69-87EB-71F9458C1CCC

Q33840789-45443A96-584F-4074-9606-4E1ACB90725D

Q33840789-67658739-C975-41DD-BAB2-1A5E436C987D

Q33840789-70074BE8-DBD7-4E0A-B990-65BBF2AFD70A

Q33840789-7D06E28E-2C0B-4079-B9DA-39F4B71E740E

Q33840789-8AD63D3F-1F86-40F7-8BB7-07060AF48AC2

Q33840789-BE56862F-8566-4453-A789-58487CA9DA3C

P2860

Q33840789-1749344C-BC25-430B-A4DB-350C49AB16D4

Q33840789-1891ABF1-7D72-4359-B360-4179C9D1519F

Q33840789-1D24F847-210A-4D10-B349-8E7CB15F1A1C

Q33840789-1EDF4326-D92C-4C04-AA77-FF2D1F43B505

Q33840789-219CFD9D-402A-40E5-926E-5B27BBBBDFC7

Q33840789-21E7D074-39BB-4736-A344-9CAA5230B130

Q33840789-296C035D-D181-4E9F-9593-2991A14AD567

Q33840789-2BDB3C84-4869-4C69-A283-3F8BEBF7AF5D

Q33840789-2EB6B5C2-8909-44E6-9497-E5B62D3C3680

Q33840789-38EF840F-CDEB-4729-A74F-8A4285702550

P304

Q33840789-48B7359C-50F1-49A2-AFB8-38FC657FA7F8

P31

Q33840789-402506CC-1EB0-4853-ACD1-FD0ED3A4F427

P356

Q33840789-608AD61F-5A19-4429-B2D8-3DE3C11D76E7

P433

Q33840789-F6F32B61-EABD-4F3E-BCC8-EBFFE5C1693F

P478

Q33840789-BAFD0270-ECC7-4973-9DD7-70BB269927E0

P50

Q33840789-E2371465-048A-4679-AF01-4C03450E5186

P577

Q33840789-12640C48-A6B0-4A46-BCD5-FF1F221A31D5

P5875

Q33840789-6BCB393D-8363-4341-9419-90D61F2D6E40

P698

Q33840789-BB7D8978-902F-4C38-AA0C-59E744D90855

P932

Q33840789-3E0711D5-A4DD-4173-B316-C9D22EEEE4F5

P356

J.CHEMBIOL.2010.03.012

P1433

Chemistry and Biology

P1476

Defining criteria for oligoman ...... hedral virus capsid scaffolds.

@en

P2093

Andrew K Udit

http://www.w3.org/2001/XMLSchema#string

Cheng-Yuan Huang

http://www.w3.org/2001/XMLSchema#string

Chi-Huey Wong

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Eiton Kaltgrad

http://www.w3.org/2001/XMLSchema#string

James C Paulson

http://www.w3.org/2001/XMLSchema#string

Katie J Doores

http://www.w3.org/2001/XMLSchema#string

Ralph Pantophlet

http://www.w3.org/2001/XMLSchema#string

Rena D Astronomo

http://www.w3.org/2001/XMLSchema#string

Sheng-Kai Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Printed covalent glycan array for ligand profiling of diverse glycan binding proteins

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans

The refined crystal structure of cowpea mosaic virus at 2.8 A resolution

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

The crystal structure of bacteriophage Q beta at 3.5 A resolution

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes

The antigenic structure of the HIV gp120 envelope glycoprotein

P304

357-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CHEMBIOL.2010.03.012

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43340959

http://www.w3.org/2001/XMLSchema#string

P698

20416507

http://www.w3.org/2001/XMLSchema#string

P932

2867452

http://www.w3.org/2001/XMLSchema#string